Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Sep 30, 2020SCS portfolio features full-body MRI conditional devices that combine therapy options for personalized pain reliefBoston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems. The portfolio, consisting of four MRI conditionali,...
Sep 28, 2020Next-generation Valve Designed to Reduce Paravalvular Leaking, Improve Procedural Efficiency and Treat More Patients with Expanded Indication over Prior VersionBoston Scientific Corporation (NYSE: BSX) today announced it has initiated a controlled launch of the ACURATE neo2™ Aortic Valve System in Europe. This next-generation transcatheter aortic valve...
-
Sep 21, 2020Agreement expands company's access to pulsed field ablation technology
Boston Scientific Corporation (NYSE: BSX) today announced it has signed an investment agreement with an exclusive option to acquire Farapulse, Inc., a privately-held company developing a pulsed...
Sep 9, 2020Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise Genus™ Deep Brain Stimulation (DBS) System in...
-
Sep 3, 2020
Boston Scientific (NYSE: BSX) announced that the U.S. Centers for Medicare and Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for the Eluvia™ Drug-Eluting Vascular Stent...
-
Aug 26, 2020
Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences. On September 9, 2020, Mike Mahoney, chairman and chief executive officer, and Susie Lisa,...
-
Jul 29, 2020
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.003 billion during the second quarter of 2020. This represents a decline of (23.9) percent on a reported basis, (23.1) percent on an...
Jul 21, 2020New stroke risk reduction technology designed to advance procedural performance and safety, treat wider range of patients with non-valvular atrial fibrillationBoston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Experience...
-
Jun 30, 2020
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2020 on Wednesday, July 29,...
Jun 29, 2020First ICM device with remote programming paired with dual-stage arrhythmia detection algorithmBoston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the LUX-Dx™ Insertable Cardiac Monitor (ICM) System, a new, long-term diagnostic device...